NMD Pharma A/S | LinkedIn
NMD Pharma (@NMDPharma) / Twitter
NMD pulls in $40M from Jeito-led, Roche-backed syndicate, gaining financial muscle to crack myasthenia gravis market | Fierce Biotech
NMD Pharma raises €35m to expand pipeline - European Pharmaceutical Manufacturer
NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare Neuromuscular Disorders - Global Genes
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma A/S | LinkedIn
NMD Pharma Company Profile: Valuation & Investors | PitchBook
NMD Pharma (@NMDPharma) / Twitter
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma Archives - Pharmtech Focus
Thomas H. Pedersen - CEO at NMD Pharma | The Org
NMD Pharma
NMD Pharma vinder pris i vækstkonkurrence | EY Danmark
NMD Pharma receives Orphan Drug Designation from FDA for
NMD Pharma A/S | LinkedIn
NMD PHARMA APS innovation strategy - GoodIP
Novo Seeds portfolio company NMD Pharma reports positive top-line Phase I/IIa data in myasthenia gravis - Startup Weekly
Thomas Pedersen email address & phone number | NMD Pharma A/S CEO contact information - RocketReach
Funding round-up: NMD Pharma, MindFi, Neo Medical, TargED Biopharmaceutical, MediBuddy - LaingBuisson News
NMD Pharma
NMD Pharma A/S | LinkedIn
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma Nears Validation For ClC-1 Inhibition With Lead Program In Myasthenia Gravis :: Scrip
NMD Pharma is about to start a combined Phase I/IIa clinical trial with its ClC-1 channel inhibitor in healthy subjects and patients with myasthenia gravis – ION CHANNEL LIBRARY
NMD Pharma Lights Up INCUBA/Skejby - Rare Disease Day 2023
